Atezolizumab, an immune checkpoint inhibitor against programmed death-ligand 1 (PD-L1), combined with nanoparticle albumin-bound paclitaxel has demonstrated remarkable activity in PD-L1 positive metastatic triple-negative breast cancer 43. This evidence concerns the gene CD274 and triple-negative breast carcinoma.